{"prompt": "['Product: MK-3475', '109', 'Protocol/Amendment No.: 604-09', '(NCT02402920). Additionally, there are no known AEs associated with subjects with SCLC', 'for which determination of a p-value is expected to impact the safety assessment. For these', 'reasons, there are no events of interest that warrant inferential testing. Therefore, there are no', 'Tier I events in this study.', 'Adverse experiences (specific terms as well as system organ class terms) that are not', 'pre-specified as Tier-1 endpoints will be classified as belonging to \"Tier 2\" or \"Tier 3\", based', 'on the number of events observed. Membership in Tier 2 requires that at least 10% of', 'subjects in any treatment group exhibit the event; all other AEs and predefined limits of', 'change will belong to Tier 3.', 'The threshold of at least 10% was chosen for membership in Tier 2 because subjects enrolled', 'in this study are in critical condition and usually experience various AEs of similar types', 'regardless of treatment, events reported less frequently than in 10% of subjects would', 'obscure the assessment of the overall safety profile and add little to the interpretation of', 'potentially meaningful treatment differences. In addition, Grades 3 to 5 AEs (5% of', 'subjects in one of the treatment arms) and SAEs (5% of subjects in one of the treatment', 'arms) will be considered Tier 2 events. For Tier 2 events, 95% CIs will be provided for', 'between-treatment differences in the percentage of subjects with events; these analyses will', 'be performed using the Miettinen and Nurminen method [116], an unconditional, asymptotic', 'method. Because many 95% CIs may be provided without adjustment for multiplicity, the', 'CIs should be regarded as a helpful descriptive measure to be used in safety review, not a', 'formal method for assessing the statistical significance of the between-treatment differences.', 'For laboratory parameters, the number and percentage of subjects with increases from', 'baseline in laboratory test toxicity grades based on the highest post-baseline toxicity grade', 'and shift of toxicity grade from baseline to the worst post-baseline toxicity grade will be', 'summarized by treatment arm.', 'Table 14 Analysis Strategy for Safety Parameters', '95% CI for', 'Descriptive', 'Safety Tier', 'Safety Endpoint', 'Treatment', 'Statistics', 'Comparison', 'Tier 2', 'Any AE (10% of subjects in one of the', 'X', 'X', 'treatment arms)', 'Any Grades 3 to 5 AE (>5% of subjects in one', 'X', 'X', 'of the treatment arms)', 'Any serious AE (>5% of subjects in one of the', 'X', 'X', 'treatment arms)', 'Tier 3', 'Any AE', 'X', 'Any change from baseline results (laboratory', 'X', 'tests)', 'Abbreviations: AE=adverse event, CI=confidence interval', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '110', 'Protocol/Amendment No.: 604-09', '8.6.3 Summaries of Baseline Characteristics and Demographics', 'The comparability of the treatment groups for each relevant characteristic will be assessed by', 'the use of tables and/or graphs. No statistical hypothesis tests will be performed on these', 'characteristics. The number and percentage of subjects randomized, and the primary reason', 'for discontinuation will be displayed. Demographic variables (such as age) and baseline', 'characteristics will be summarized by treatment either by descriptive statistics or categorical', 'tables. The reasons for exclusion from the ITT population (if any) will be summarized.', '8.7', 'Interim Analyses', 'Two interim efficacy analyses are planned for this study.', 'The (IA1) will be performed approximately 18 months from study start. PFS and', 'os will be evaluated at IA1. ORR p-value from IA1 may be evaluated for', 'statistical significance if PFS and OS null hypotheses are rejected at IA1 or at a', 'later analysis time.', 'The second interim analysis (IA2) is the final formal analysis of PFS. It will be', 'performed at approximately 22 months after first subject enrolled. The second', 'interim analysis evaluation of OS will be performed at this time.', 'The final analysis will evaluate OS only. It is planned when a minimum of 294', 'deaths have been observed or approximately 31 months after first subject', 'enrolled, whichever occurs later.', 'In addition to the formal efficacy analyses, the DMC will conduct regular safety monitoring,', 'the timing of which is specified in the DMC charter. Decisions to stop the trial early will be', 'based on DMC recommendations with review by the EOC.', 'Type I error control for the efficacy analyses as well as efficacy bounds are described in the', 'next section.', '8.8 Multiplicity', 'The trial uses the graphical method of Maurer and Bretz [114] to control multiplicity for', 'multiple hypotheses as well as interim analyses. Figure 3 shows the initial one-sided a', 'allocation for each hypothesis in the ellipse representing the hypothesis. The weights for', 'reallocation from each hypothesis to the others are represented in the boxes on the lines', 'connecting hypotheses.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}